易布鲁替尼和威尼托克拉克斯用于复发性和耐火性囊性淋巴瘤
Chaitra Ujjani1, Hongkun Wang2, Catherine Broome2
1Fred Hutchinson Cancer Center, University of Washington, Seattle, WA.
结合布鲁顿氨酸激酶 (BTK) 抑制剂和B细胞淋巴瘤2 (BCL-2) 抑制剂,在复发性/耐药性卵泡淋巴瘤 (FL) 中显示出有效性. 这种双重向治疗为FL患者提供了一个有前途的新方法.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 布鲁顿氨酸激酶 (BTK) 抑制剂是B细胞恶性瘤的确立治疗方法.
- 赞努布鲁丁尼布是一种BTK抑制剂,最近获得了治疗复发性或耐火性卵泡淋巴瘤 (FL) 的批准.
- 临床前数据表明,在FL中,BTK抑制剂 (例如,易布鲁替尼) 和B细胞淋巴瘤2 (BCL-2) 抑制剂 (例如,venetoclax) 之间存在协同作用.
研究的目的:
- 评估使用ibrutinib和venetoclax的组合治疗的安全性和疗效.
- 为了确定在复发性或耐火性FL患者的2期试验的最佳剂量.
主要方法:
- 进行了一项多中心Ib/II期研究.
- 这项研究评估了在复发性/耐药性FL中使用易布鲁替尼和威尼托克拉克斯的组合.
- 患者接受了ibrutinib 560毫克和venetoclax 600毫克的剂量,没有增加venetoclax.
主要成果:
- 推的第二阶段剂量为ibrutinib 560 mg和venetoclax 600 mg.
- 常见的不良事件包括腹 (83%),感染 (75%) 和皮疹 (58%),大多是低级.
- 总体响应率为63%,完全响应率 (CR) 为21%. 无进展生存时间的中位数为8.2个月.
结论:
- 结合BTK和BCL-2抑制剂,在复发性/耐药性FL中显示出有效性.
- 这种双重目标的方法是一种独特的策略,需要进一步的临床研究.
- 这种组合通常耐受良好,没有观察到临床瘤溶解综合征.
更多相关视频
14:04Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
Published on: March 25, 2016
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
相关概念视频
Treatment Resistant Cancers
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Primary Lymphoid Organs
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
